This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

PharmaPoint: Rheumatoid Arthritis - United Kingdom Drug Forecast And Market Analysis Event-Driven Update

Table 38: Product Profile - Tabalumab 76

Table 39: ACR Responses and DAS28 Scores for Tabalumab vs. Placebo at Week 16 77

Table 40: Tabalumab SWOT Analysis, 2012 78

Table 41: Product Profile - Fostamatinib 79

Table 42: ACR Responses and DAS28 Scores for Fostamatinib vs. Placebo at Month Three 80

Table 43: Fostamatinib SWOT Analysis, 2012 82

Table 44: Product Profile - RAVAX 83

Table 45: RAVAX SWOT Analysis, 2012 86

Table 46: Product Profile - Secukinumab 87

Table 47: Secondary Endpoint Results for Secukinumab vs. Placebo at Weeks 24 and 52 88

Table 48: Secukinumab SWOT Analysis, 2012 90

Table 49: Product Profile - Masitinib 91

Table 50: ACR Responses for Masitinib in the ITT Population (12 Weeks) 92

Table 51: ACR Responses for Masitinib in the ITT Population (12-82 Weeks) 93

Table 52: Masitinib SWOT Analysis, 2012 95

Table 53: Product Profile - Baricitinib 96

Table 54: ACR Responses for Baricitinib + MTX vs. Placebo + MTX at Week 12 97

Table 55: Safety of 4 and 8mg Baricitinib at Week 12 98

Table 56: Laboratory Values of 4 and 8mg Baricitinib at Week 12 98

Table 57: Baricitinib SWOT Analysis, 2012 99

Table 58: Product Profile - Sarilumab 100

Table 59: MOBILITY Study Results for Sarilumab at Week 12 101

Table 60: Sarilumab SWOT Analysis, 2012 102

Table 61: Product Profile - Sirukumab 103

Table 62: Sirukumab SWOT Analysis, 2012 105

Table 63: Sales Forecasts ($m) for Rheumatoid Arthritis in the United Kingdom 107

Table 64: Key Events Impacting Sales for Rheumatoid Arthritis in the United Kingdom, 2012 109

Table 65: Rheumatoid Arthritis Market - Drivers and Barriers in the United Kingdom, 2012 109

Table 66: Key Launch Dates 124

Table 67: Key Patent Expiries 124

Table 68: Physicians Surveyed, By Country 132

3 of 4

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs